Articles with public access mandates - Susan FoxLearn more
Not available anywhere: 29
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
RMA de Bie, CE Clarke, AJ Espay, SH Fox, AE Lang
The Lancet Neurology 19 (5), 452-461, 2020
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials
LV Kalia, JM Brotchie, SH Fox
Movement Disorders 28 (2), 131-144, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD
JM Miyasaki, J Long, D Mancini, E Moro, SH Fox, AE Lang, C Marras, ...
Parkinsonism & related disorders 18, S6-S9, 2012
Mandates: Canadian Institutes of Health Research
Dihydropyridine calcium channel blockers and the progression of parkinsonism
C Marras, A Gruneir, P Rochon, X Wang, G Anderson, J Brotchie, CM Bell, ...
Annals of neurology 71 (3), 362-369, 2012
Mandates: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada
Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease
W Reginold, S Duff-Canning, C Meaney, MJ Armstrong, S Fox, ...
Dementia and geriatric cognitive disorders 36 (1-2), 67-75, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial
AH Tan, SY Lim, S Mahadeva, MF Loke, JY Tan, BH Ang, KP Chin, ...
Movement Disorders 35 (12), 2250-2260, 2020
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
A critique of available scales and presentation of the Non‐Human Primate Dyskinesia Rating Scale
SH Fox, TH Johnston, Q Li, J Brotchie, E Bezard
Movement disorders 27 (11), 1373-1378, 2012
Mandates: US National Institutes of Health, Fondazione Cariplo
The long-term outcome of orthostatic tremor
C Ganos, L Maugest, E Apartis, C Gasca-Salas, MT Cáceres-Redondo, ...
Journal of Neurology, Neurosurgery & Psychiatry 87 (2), 167-172, 2016
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Serotonergic approaches in Parkinson’s disease: translational perspectives, an update
P Huot, V Sgambato-Faure, SH Fox, AC McCreary
ACS Chemical Neuroscience 8 (5), 973-986, 2017
Mandates: US National Institutes of Health, Natural Sciences and Engineering Research …
Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial
C Zadikoff, PM Wadia, J Miyasaki, R Chen, AE Lang, J So, SH Fox
Basal Ganglia 1 (2), 91-95, 2011
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
New treatments for the motor symptoms of Parkinson’s disease
AC Vijverman, SH Fox
Expert review of clinical pharmacology 7 (6), 761-777, 2014
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?
TA Mestre, I Beaulieu-Boire, CC Aquino, N Phielipp, YY Poon, JP Lui, ...
Parkinsonism & Related Disorders 21 (11), 1349-1354, 2015
Mandates: US National Institutes of Health
Update on current and emerging therapies for dystonia
KJ Lizarraga, D Al-Shorafat, S Fox
Neurodegenerative Disease Management 9 (3), 135-147, 2019
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Dopamine reuptake inhibitors in Parkinson’s disease: a review of nonhuman primate studies and clinical trials
P Huot, SH Fox, JM Brotchie
Journal of Pharmacology and Experimental Therapeutics 357 (3), 562-569, 2016
Mandates: Canadian Institutes of Health Research
Medical, surgical, and physical treatments for Parkinson's disease
T Foltynie, V Bruno, S Fox, AA Kühn, F Lindop, AJ Lees
The Lancet 403 (10423), 305-324, 2024
Mandates: National Institute for Health Research, UK, Michael J Fox Foundation, UK …
developing drugs for levodopa‐induced dyskinesia in PD: lessons learnt, what does the future hold?
SH Fox, JM Brotchie
European Journal of Neuroscience 49 (3), 399-409, 2019
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12‐Week Controlled Trial
TA Mestre, E Freitas, A Basndwah, MR Lopez, LM de Oliveira, ...
Movement Disorders 35 (12), 2319-2323, 2020
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
P Huot, TH Johnston, SH Fox, JM Brotchie
Synapse 69 (3), 2015
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Emerging drugs for levodopa-induced dyskinesia
A Al Dakheel, I Beaulieu-Boire, SH Fox
Expert Opinion on Emerging Drugs 19 (3), 415-429, 2014
Mandates: US National Institutes of Health
Nondopaminergic treatments for Parkinson’s disease
P Huot, SH Fox
Neurodegenerative Disease Management 1 (6), 491-512, 2011
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Publication and funding information is determined automatically by a computer program